Correlation Between Bolt Biotherapeutics and Cue Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bolt Biotherapeutics and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bolt Biotherapeutics and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bolt Biotherapeutics and Cue Biopharma, you can compare the effects of market volatilities on Bolt Biotherapeutics and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bolt Biotherapeutics with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bolt Biotherapeutics and Cue Biopharma.

Diversification Opportunities for Bolt Biotherapeutics and Cue Biopharma

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Bolt and Cue is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Bolt Biotherapeutics and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Bolt Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bolt Biotherapeutics are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Bolt Biotherapeutics i.e., Bolt Biotherapeutics and Cue Biopharma go up and down completely randomly.

Pair Corralation between Bolt Biotherapeutics and Cue Biopharma

Given the investment horizon of 90 days Bolt Biotherapeutics is expected to generate 0.32 times more return on investment than Cue Biopharma. However, Bolt Biotherapeutics is 3.17 times less risky than Cue Biopharma. It trades about -0.17 of its potential returns per unit of risk. Cue Biopharma is currently generating about -0.18 per unit of risk. If you would invest  65.00  in Bolt Biotherapeutics on August 25, 2024 and sell it today you would lose (7.00) from holding Bolt Biotherapeutics or give up 10.77% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Bolt Biotherapeutics  vs.  Cue Biopharma

 Performance 
       Timeline  
Bolt Biotherapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Bolt Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Cue Biopharma 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point.

Bolt Biotherapeutics and Cue Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bolt Biotherapeutics and Cue Biopharma

The main advantage of trading using opposite Bolt Biotherapeutics and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bolt Biotherapeutics position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.
The idea behind Bolt Biotherapeutics and Cue Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Global Correlations
Find global opportunities by holding instruments from different markets